TabletsClinical Overview
Ethinylestradiol 0.035 mg and Cyproterone Acetate 2 mg Tablet is a combined hormonal formulation containing an estrogen and a potent anti-androgenic progestogen. Cyproterone competitively blocks androgen receptors and suppresses ovarian androgen synthesis, while Ethinylestradiol increases Sex Hormone-Binding Globulin (SHBG) synthesis, drastically reducing free circulating testosterone. Indicated for the treatment of severe androgen-dependent acne (with or without seborrhea), moderate to severe hirsutism, and polycystic ovary syndrome (PCOS) in women of reproductive age requiring oral contraception.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally 1 tablet daily at the same time each day for 21 consecutive days, starting on Day 1 of the menstrual cycle, followed by a 7-day pill-free interval during which withdrawal bleeding occurs. Begin next pack on Day 29. Swallow whole with water. Continuous daily compliance is essential for contraceptive efficacy and endocrine stability.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Nausea, abdominal cramping, breakthrough spotting, headache, breast tenderness, weight gain, mild mood changes, and reduced libido. Rare/Severe: Venous thromboembolism (DVT, pulmonary embolism - higher risk than levonorgestrel-containing COCs), arterial thromboembolism (stroke, myocardial infarction), benign hepatic adenoma, and gallbladder disease.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black Box Warning: Increased risk of venous thromboembolism (VTE). Strictly contraindicated in women who smoke (especially age >=35), history of deep vein thrombosis, pulmonary embolism, cerebrovascular disease, ischemic heart disease, uncontrolled hypertension, migraines with aura, active liver disease, and breast cancer. Do not combine with other hormonal contraceptives.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Gynecological, Obstetric & Endocrinological Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice or reproductive healthcare guidance. Hormonal medications, uterotonics, corticosteroids, fertility therapies, and emergency contraceptives have profound systemic actions and must be administered strictly under the supervision of a registered gynecologist, obstetrician, or endocrinologist.
Ethinylestradiol 0.05mg + Levonorgestrel 0.25mg Tablets
Ethinylestradiol and Levonorgestrel Tablets IP is a second-generation low-dose Combined Oral Contraceptive (COC) pill on the WHO Model List of Essential Medicines. It synergistically suppresses the mid-cycle LH surge to inhibit ovulation, renders cervical mucus hostile to sperm migration, and alters the endometrium. Second-generation levonorgestrel combinations demonstrate the lowest epidemiological relative risk of venous thromboembolism among combined oral contraceptives. Indicated for prevention of pregnancy, cycle regulation, and treatment of dysmenorrhea.
Ethinylestradiol 0.03mg + Desogestrel 0.15mg Tablets
Ethinylestradiol 0.03 mg and Desogestrel 0.15 mg Tablets is a third-generation low-dose monophasic Combined Oral Contraceptive (COC) pill on the WHO Model List of Essential Medicines. It prevents pregnancy primarily by suppressing pituitary gonadotropin secretion (inhibiting ovulation), thickening cervical mucus to prevent sperm penetration, and altering the endometrium to impair implantation. Desogestrel has high progestogenic potency and low androgenic activity, causing less acne and weight gain than older progestogens.
Ethinylestradiol 0.03mg + Levonorgestrel 0.15mg Tablets
Ethinylestradiol and Levonorgestrel Tablets IP is a second-generation low-dose Combined Oral Contraceptive (COC) pill on the WHO Model List of Essential Medicines. It synergistically suppresses the mid-cycle LH surge to inhibit ovulation, renders cervical mucus hostile to sperm migration, and alters the endometrium. Second-generation levonorgestrel combinations demonstrate the lowest epidemiological relative risk of venous thromboembolism among combined oral contraceptives. Indicated for prevention of pregnancy, cycle regulation, and treatment of dysmenorrhea.